Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401203 | 0.79 | PDE10A (0.45) | PDE10AMAP4K4HSD11B1AOC3NAMPT | |
| SCHEMBL31396039 | 0.78 | MAPT (0.45) | AOC3 | |
| SCHEMBL31401315 | 0.77 | HRH3 (0.39) | — | |
| SCHEMBL31401090 | 0.75 | MAP4K4 (0.38) | MAP4K4 | |
| SCHEMBL31400884 | 0.75 | PDE10A (0.42) | PDE10ANAMPT | |
| SCHEMBL31401436 | 0.74 | SORD (0.51) | — | |
| SCHEMBL31395896 | 0.73 | NPC1 (0.39) | AOC3 | |
| SCHEMBL23706098 | 0.72 | MAP4K4 (0.43) | PDE10AMAP4K4SMPD3 | |
| SCHEMBL31401152 | 0.72 | MAPT (0.42) | — | |
| SCHEMBL2596341 | 0.71 | PDE10A (1.00) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |